Clinical study of etomidate combined with propofol and remifentanil for transvaginal oocyte retrieval

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057521

Enrollment

Unknown

Registered

2022-03-14

Start date

2022-03-15

Completion date

Unknown

Last updated

2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control group:Propofol 2.0mg/kg + remifentanil 0.5ug/kg

Experimental group:Etomidate 0.2mg/kg + propofol 1.0mg/kg + remifentanil 0.5ug/kg

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients who need to undergo IVF/ICSI transvaginal egg extraction for infertility diagnosis in our center; 2. Aged 18-40 years; 3. Body Mass Index: 18-26 kg/m^2; 4. Basal antral follicle count (AFC) > 5; 5. No previous history of IVF/ICSI; 6. No previous production history.

Exclusion criteria

Exclusion criteria: 1. Refuse to accept this study; 2. Those who are receiving other analgesic, sedative or anesthetic treatment; 3. Patients with asthma, severe allergic history or complicated with serious complications of heart, brain, lung, liver and kidney; 4. Patients who participated in other drug clinical trials or other anesthesia therapy trials within 3 months prior to enrollment in this study.

Design outcomes

Primary

Measure	Time frame
First embryo transfer pregnancy outcome;Postoperative complications;	—

Countries

China

Contacts

Public ContactLu Xianfu

First Affiliated Hospital of Anhui Medical University

lxf0001@126.com+86 18256031820

Outcome results